AGEN (Agenus) PEG Ratio: N/A (As of Aug. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AGEN Agenus Inc AGEN
43 GF Score
Price $7.16
GF Value $3.78
Valuation Significantly Overvalued
! 12 Warning Signs
View Full Analysis

What is Agenus PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Agenus's PE Ratio without NRI is 0.00. Agenus's 5-Year EBITDA growth rate is 0.00%. Therefore, Agenus's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Agenus's PEG Ratio or its related term are showing as below:



AGEN's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.87
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Agenus  (NAS:AGEN) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Agenus PEG Ratio Related Terms


Agenus PEG Ratio Historical Data

* Premium members only.

The historical data trend for Agenus's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agenus PEG Ratio Chart

Agenus Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Agenus Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AGEN vs FULC, IRD, TTRX: PEG Ratio Comparison

For the Biotechnology subindustry, Agenus's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agenus PEG Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agenus's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Agenus's PEG Ratio falls into.


AGEN
43GF Score
Agenus Inc AGEN
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Agenus PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Agenus's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Agenus (AGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Agenus stock appears to be overvalued. The current stock price of $7.16 is trading 89.3% above its estimated GF Value™ of $3.78. GuruFocus considers Agenus to be Significantly Overvalued.

Key valuation signals for AGEN:

  • PEG Ratio: N/A
  • GF Value™: $3.78 vs. price of $7.16 (89.3% above fair value)
  • GF Score™: 43/100 with 12 warning signs

No single metric tells the full story. See the AGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Agenus Business Description

Other Exchanges AJ8:Germany
Address 3 Forbes Road, Lexington, MA, USA, 02421
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
43GF Score

Get the complete analysis for AGEN

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.16
Price
$3.78
GF Value